Clinical trials: Topotecan, completed
Advanced Cancer
Study of Temsirolimus, Topotecan, and Bortezomib
The goal of this clinical research study is to find the highest tolerable dose of Torisel (temsirolimus), Hycamtin (topotecan hydrochloride), and Velcade (bortezomib) that can be given, in combination, to patients with advanced…
- Trial name
- NCT00770731
- Testing
- Torisel (Temsirolimus), Hycamtin (Topotecan), Velcade (Bortezomib)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Malignancies
Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies
Participants will take GW572016 by mouth daily each cycle (cycles 28 days in length) and will be given Topotecan intravenously on Days 1, 8 and 15.
- Trial name
- NCT00295243
- Testing
- Topotecan
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Unspecified Adult Solid Tumor, Protocol Specific
Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00541359
- Testing
- bortezomib, topotecan hydrochloride, immunohistochemistry staining method
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- City of Hope Medical Center
Neuroblastoma
Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma
RATIONALE: Radioactive drugs, such as iodobenzylguanidine meta-I131, may carry radiation directly to tumor cells and not harm normal cells.
- Trial name
- MIITOP (NCT00960739)
- Testing
- Topotecan hydrochloride, Autologous hematopoietic stem cell transplantation, iobenguane I 131
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Centre Oscar Lambret
Neuroblastoma
Therapy for Children With Advanced Stage High Risk Neuroblastoma
This is a Phase II pilot study of chemotherapy and surgery for children with advanced stage high-risk neuroblastoma utilizing topotecan during an upfront window and other active agents during induction and intensification phases.
- Trial name
- NCT00186849
- Testing
- Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin, Peripheral Blood Stem Cell Transplant
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- St. Jude Children's Research Hospital
Cervical Cancer
Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer
The purpose of this study is to determine whether the combination of topotecan, cisplatin and bevacizumab is effective in the treatment of recurrent or persistent cervical cancer
- Trial name
- NCT00548418
- Testing
- Topotecan, Cisplatin, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Washington University School of Medicine
Retinoblastoma
Phase I Trial of Periocular Topotecan in Retinoblastoma
This is a dose-escalation study aimed to assess the toxicity (and marginally the activity) of periocular topotecan in patients with relapsed-resistant retinoblastoma.
- Trial name
- NCT00460876
- Testing
- Topotecan
- Where
- Argentina
- Volunteers
- 5 people
- Sponsor
- Hospital JP Garrahan
Lung Cancer
Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if topotecan is more effective given by infusion or by mouth.
- Trial name
- NCT00003917
- Testing
- topotecan hydrochloride
- Where
- 53 sites in United States
- Volunteers
- 4 people
- Sponsor
- Case Comprehensive Cancer Center
Small Cell Lung Cancer
Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer
This is a 2-part, multicenter, open-label, randomized study of dinutuximab and irinotecan versus irinotecan alone in subjects with relapsed or refractory small cell lung cancer (SCLC).
- Trial name
- NCT03098030
- Testing
- Dinutuximab, Irinotecan, Topotecan
- Where
- 226 sites in United States, Australia and 21 more
- Volunteers
- 483 people
- Sponsor
- United Therapeutics
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Thrombocytopenia
- Trial name
- NCT00003619
- Testing
- filgrastim, vitamin E, busulfan
- Where
- 2 sites in United States
- Sponsor
- Drexel University College of Medicine
Neuroblastoma
Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients
Improvement of event free survival of high-risk neuroblastoma patients by introduction of two additional topotecan containing chemotherapy cycles into the multimodal standard treatment (induction chemotherapy, myeloablative…
- Trial name
- NB2004-HR (NCT03042429)
- Testing
- Cycles N8, N5 and N6, Cycles N5 and N6
- Where
- Germany
- Volunteers
- 360 people
- Sponsor
- University of Cologne
Neuroblastoma
Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children
The purpose of this study is to investigate whether Bevacizumab (an anti-VEGF monoclonal antibody) added to a backbone chemotherapy regimen (Temozolomide, Irinotecan-Temozolomide or Topotecan-Temozolomide) demonstrates activity…
- Trial name
- BEACON (NCT02308527)
- Testing
- Bevacizumab, Temozolomide, Irinotecan
- Where
- 10 sites in Austria, Belgium and 8 more
- Volunteers
- 225 people
- Sponsor
- University of Birmingham
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia
High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia
This pilot clinical trial studies the feasibility of choosing treatment based on a high throughput ex vivo drug sensitivity assay in combination with mutation analysis for patients with acute leukemia that has returned after a…
- Conditions
- Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT02551718
- Testing
- Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Washington
Brain and Central Nervous System Tumors
Chemotherapy in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of topotecan plus carmustine in patients with recurrent…
- Trial name
- NCT00002986
- Testing
- carmustine, topotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Duke University
Ganglioneuroblastoma, High Risk Neuroblastoma
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
This phase II pilot trial studies the side effects and how well dinutuximab and sargramostim work when combined with chemotherapy in patients with high-risk neuroblastoma.
- Trial name
- NCT03786783
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Solid Tumor, Childhood Solid Tumor
Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors
This is a Phase I study of the combination of three drugs: sirolimus, cyclophosphamide, and topotecan. This is the first study to evaluate the safety and clinical activity of the combination of oral sirolimus, oral…
- Trial name
- NCT01670175
- Testing
- Sirolimus, Cyclophosphamide, Topotecan
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Francisco
Brain and Central Nervous System Tumors
Topotecan in Treating Patients With Recurrent Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of topotecan in treating patients with recurrent brain…
- Trial name
- NCT00003372
- Testing
- topotecan hydrochloride
- Where
- 11 sites in Canada
- Volunteers
- 17 people
- Sponsor
- NCIC Clinical Trials Group
Leukemia
Topotecan in Treating Children With Refractory Leukemia
Phase I trial to study the effectiveness of topotecan in treating children with refractory leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00002705
- Testing
- topotecan hydrochloride
- Where
- 31 sites in United States, Canada and 2 more
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Extensive Stage Small Cell Lung Cancer
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00057837
- Testing
- G-CSF, Cisplatin, Etoposide
- Where
- 79 sites in United States
- Volunteers
- 140 people
- Sponsor
- Eastern Cooperative Oncology Group
Fallopian Tube Cancer, Ovarian Cancer
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00114166
- Testing
- topotecan hydrochloride
- Where
- 78 sites in United States
- Volunteers
- 81 people
- Sponsor
- Gynecologic Oncology Group